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Introduction 
The increasing incidence of cancer in Portugal is worrisome 
and may be explained by lifestyle changes, growing life 
expectancy, and improved early detection. The regional 
cancer registry for the south region exists since 1996. It was 
initially set up to observe and monitor the disease 
incidence, prevalence and survival, i.e, register all 
information about new cancer cases[1] . More recently, since 
adaptive pathways have been proposed[2], together with 
the creation of SiNATS [3], led to an emerging area of interest 
in ROR-Sul, therapeutic effectiveness monitoring. This area 
includes collecting high quality data to further refine the 
known benefit-risk ratio and to judge the therapeutic added 
value[4]. It is particularly important for the Portuguese 
health service (PHS) to evaluate the effectiveness of new 
high-priced medicines [5]. This study aimed to evaluate the 
exhaustiveness of the Registo Oncológico Regional Sul. 
 
Materials and Methods 
To assess the exhaustiveness of cancer registry in a cohort 
of lung cancer patients diagnosed during the year 2014 
(01/01/2014 to 01/01/2015) .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis: Data was analyzed using IBM SPSS 
software, v.24,0, comprising descriptive analysis of missing 
data. No ethics submission was deemed necessary. 
Discussion and Conclusions 
Cancer registry is organized to foresee compulsory variables and optional ones. As expected, the exhaustiveness of 
compulsory variables was near 100%. So far, treatment and mutation variables are not compulsory. However, if the cancer 
registry is intended to support effectiveness studies in the future, this option should be carefully considered. The low level of 
detail in clinical files should also be considered, in regards to treatment, where perhaps an educational investment must be 
made.  
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3457 patients 
915 female (26,5%) 2540 male (73,5%) 
Variable Missing values (%) 
Gender 0 
Date of diagnosis 0 
Date of first medical 
appointement 
0  
District 0 
Stage of Disease at first 
diagnosis 
  0* 
Cancer morphology 0  
Cancer topography 0 
Cancer differentiation    0* 
Vital state 0 
Date of last contact 0 
Radiotherapy (type) 0 
Table 1. Variables considered to have a high exhaustiveness 
*Although no missing values exists, there are a high percentage of “Unkown” 
(Stage of Disease at first diagnosis -8,2% ; Cancer differentiation – 63,8%) 
 
Variable Missing values (%) 
ALK mutation 12,8  
KRAS mutation 7,5 
EGFR mutation 2,5  
Treatment received 
(Immunotherapy) 
7,8 
Surgery (Procedure) 4,5 
Table 2. Variables considered to have a medium exhaustiveness 
Variable Missing values (%) 
Performance Status 66,3 
Treatment received 
(Chemotherapy) 
36 
Chemotherapy 
treatment response 
44,9  
Table 3. Variables considered to have a low exhaustiveness 
